Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
published in: Arthritis & Rheumatology
date of publication: 2006-09-01
main subject: phase III clinical trial, multicenter clinical trial, placebo, rheumatoid arthritis, rituximab
Cites articles 3
- 2000-12-01
Date
Title
Article - wd:Q44774931